WebDoctor Encyclopedia

Endocrine Ovarian

Malignant struma ovarii

Malignant struma ovarii is a rare ovarian tumour made mostly of thyroid tissue that has become cancerous. It is often found after surgery for an ovarian mass. Treatment combines surgery with, in some cases, thyroid removal and radioactive iodine, and the outlook is usually very good.

Medically reviewed Last reviewed October 20, 2026

What is malignant struma ovarii?

Malignant struma ovarii is a rare cancer of the ovary made of thyroid tissue. It sounds surprising, but the ovary can occasionally contain tissue that looks and works like the thyroid gland in the neck. This happens within a type of teratoma, a germ cell tumour that can produce many different kinds of body tissue.

When a teratoma consists mostly of thyroid tissue, it is called struma ovarii. Struma ovarii itself is uncommon, accounting for about 0.3-1% of ovarian tumours, and most are benign (Addley et al., 2021). In a small proportion, the thyroid tissue develops into thyroid-type cancer, most often papillary thyroid carcinoma. This is called malignant struma ovarii.

The condition usually affects women in their 30s and 40s. It is rarely suspected before surgery, because it looks like other ovarian masses on scans. The diagnosis is normally made when the pathologist examines the removed ovary.

The outlook is generally excellent. Many women need only surgery to remove the affected ovary. Thyroid-directed treatment, such as removal of the thyroid gland followed by radioactive iodine, is used for women at higher risk or with spread. A recent pooled analysis found that about 9 in 10 women were alive 10 years after surgery (Jenkins et al., 2025).

1. Key facts at a glance

Feature Details
Type of cancer Thyroid-type carcinoma arising in struma ovarii (an ovarian teratoma)
How common Very rare; struma ovarii is 0.3-1% of ovarian tumours, and only a minority are malignant
Typical age Mean about 43-44 years
Most common type Papillary thyroid carcinoma
Diagnosis before surgery Rarely made
Main treatment Surgery; thyroidectomy and radioactive iodine for selected women
Tumour marker Thyroglobulin in the blood for follow-up
Spread Mainly within the pelvis and abdomen
Outlook Excellent; about 91% alive at 10 years in pooled data

2. Types

Types of thyroid cancer found in struma ovarii

In an analysis of 144 published patients, the following types were found (Cui et al., 2021):

Type Share
Papillary thyroid carcinoma About 50%
Follicular thyroid carcinoma About 26%
Follicular variant of papillary carcinoma About 19%
Mixed papillary and follicular About 3%
Anaplastic or medullary carcinoma Under 1% each

Highly differentiated follicular carcinoma of ovarian origin

Some tumours look almost like normal thyroid tissue but still spread to the peritoneum. This form, once called “peritoneal strumosis”, is now recognised as a very well-differentiated cancer that usually grows slowly.

Pure and impure forms

Form Description
Pure The tumour consists of thyroid tissue only
Impure (mixed) Thyroid tissue mixed with other teratoma elements, such as skin or fat

About 70% of cases in the pooled series were of the impure type (Cui et al., 2021).

Tumour How it differs
Benign struma ovarii Thyroid tissue without cancer
Strumal carcinoid Thyroid tissue mixed with a neuroendocrine tumour
Mature cystic teratoma (dermoid cyst) Contains many tissue types; usually benign
Metastatic thyroid cancer Spread from the thyroid gland to the ovary; very rare

3. Causes and risk factors

The cause is not known.

Factor Notes
Ovarian teratoma The tumour arises within thyroid tissue of a teratoma
Age Usually adult women of reproductive age
Gene changes in the tumour Changes in BRAF, NRAS, KRAS and KIT similar to thyroid cancer; some tumours have none
Inherited factors No clear link

About a third of tumours tested in the pooled series had no detectable gene change (Cui et al., 2021).

4. How does it look

On scans

Test Typical findings
Pelvic ultrasound Mixed solid and cystic mass of one ovary
CT or MRI Multi-compartment cyst with solid areas; may show fat or calcium from teratoma elements
Iodine scan after surgery Shows whether remaining tumour takes up iodine

None of these findings is specific, and in one centre’s series no case was correctly identified before surgery (Addley et al., 2021).

Under the microscope

Feature Description
Thyroid follicles Round sacs filled with colloid, just like the thyroid gland
Papillary carcinoma features Clear, overlapping nuclei with grooves and inclusions
Follicular carcinoma features Invasion of capsule or blood vessels
Stains Thyroglobulin and TTF-1 positive

Blood tests

Test Notes
CA125 Raised in about half of patients tested; not specific
Thyroglobulin Useful marker for monitoring after treatment
Thyroid function Usually normal; overactive thyroid occurs occasionally

Why it is rarely diagnosed before surgery

Ovarian masses are common, and most are benign cysts. Malignant struma ovarii has no typical scan appearance and no specific blood test, so it is almost always discovered unexpectedly when the removed ovary is examined. In the pooled analysis of 144 women, about one in six cases was initially misdiagnosed (Cui et al., 2021). Pathologists must look carefully for small areas of cancer within otherwise normal-looking thyroid tissue, because these can be easily missed.

When the diagnosis is made after surgery, a second planning meeting usually follows. The team then decides whether any further treatment is needed, which may include imaging, blood tests and an assessment of the neck thyroid.

5. Symptoms

Many women have symptoms from the ovarian mass itself. In pooled case reports, about four in five were symptomatic (Jenkins et al., 2025).

Common symptoms

  • Pelvic or lower abdominal pain
  • A swollen or bloated abdomen
  • A lump felt in the lower abdomen
  • Changes in periods

Less common symptoms

Symptom Possible cause
Fluid in the abdomen (ascites) Spread to the peritoneum or a reaction to the tumour
Fluid around the lungs Rarely, as part of a syndrome with ovarian tumours
Weight loss, palpitations, heat intolerance Overactive thyroid from hormone production (rare)
Sudden severe pain Twisting (torsion) of the ovary
Bone pain or cough Distant spread (rare)

When to seek medical advice

See your doctor about persistent bloating, pelvic pain, feeling full quickly or a change in bowel or bladder habit, especially if these happen most days for several weeks.

6. Diagnosis

Step Purpose
Pelvic ultrasound First test for an ovarian mass
CA125 and other markers Assess the likelihood of cancer
CT or MRI Describe the mass and check for spread
Surgery Removes the ovary; provides the diagnosis
Pathology review Confirms thyroid-type carcinoma and its features
Thyroid examination and ultrasound Excludes a cancer in the neck thyroid
Thyroglobulin blood test Baseline for follow-up

Risk assessment after surgery

Lower risk Higher risk
Small cancer confined to the struma Large tumour
Stage I disease Spread beyond the ovary
No aggressive features Aggressive histology or vascular invasion
Normal thyroglobulin after surgery Raised thyroglobulin after surgery

7. Treatment

There are no clinical trials, and practice varies. Experts recommend multidisciplinary team care, combining gynaecological oncology, endocrinology and nuclear medicine (Addley et al., 2021).

Surgery

Situation Typical operation
Stage I, wishes to keep fertility Removal of the affected ovary and tube (unilateral salpingo-oophorectomy)
Stage I, family complete Removal of the ovary; more extensive surgery may be discussed
Spread within the abdomen Removal of both ovaries, womb, omentum and visible deposits

For stage I disease, removal of the affected ovary alone may be adequate, with more radical surgery reserved for advanced cases (Addley et al., 2021).

Thyroid-directed therapy

Treatment Purpose
Total thyroidectomy Removes the neck thyroid so radioactive iodine goes to remaining tumour cells, and checks for a separate thyroid cancer
Radioactive iodine (I-131) Destroys remaining thyroid-type cancer cells
Thyroid hormone (levothyroxine) suppression Lowers TSH, which can stimulate cancer growth

These treatments are generally recommended when there is spread and the tumour takes up iodine (Cui et al., 2021).

The debate about thyroid treatment

A meta-analysis of 376 patients found that survival was not clearly improved by thyroidectomy, radioactive iodine or thyroid hormone therapy. The authors suggested that thyroid-directed treatment may sometimes be overtreatment (Jenkins et al., 2025). Many specialists now use these treatments selectively, based on the risk features of each case.

Treatment by situation

Situation Typical approach
Small, low-risk cancer confined to the ovary Surgery, then thyroglobulin monitoring
Higher-risk features but no spread Surgery; thyroidectomy and radioactive iodine considered
Spread in the abdomen Debulking surgery, thyroidectomy, radioactive iodine
Recurrence Surgery, further radioactive iodine or other treatments

Side effects

Treatment Possible side effects
Ovarian surgery Pain, wound problems; early menopause if both ovaries are removed
Thyroidectomy Hoarse voice, low calcium, lifelong thyroid hormone tablets
Radioactive iodine Dry mouth, altered taste, temporary isolation precautions
Thyroid hormone suppression Palpitations, bone thinning if the dose is high

Fertility and pregnancy

Because many women are young, fertility-sparing surgery is often possible. After radioactive iodine, women are usually advised to avoid pregnancy for 6-12 months.

8. Outlook (prognosis)

Measure Result
Overall survival at 10 years (pooled) About 91%
Overall survival at 20 years (pooled) About 87%
Recurrence in case reports About 27%, at a median of 4 years

These figures come from Jenkins et al. (2025). In the pooled analysis by Cui and colleagues, death was linked with spread and with the type of cancer, but survival was high overall. In the Oxford series of 11 women, all had stage I disease and none had a recurrence (Addley et al., 2021).

9. Follow-up

Follow-up Purpose
Thyroglobulin blood tests Rising levels suggest recurrence
Pelvic ultrasound or CT Checks the pelvis and abdomen
Neck ultrasound If the thyroid was not removed
Thyroid function tests For women on thyroid hormone
Long-term review Recurrence can occur many years later

Thyroglobulin is most reliable as a marker after the neck thyroid has been removed. A case report also showed its use in monitoring a woman treated with surgery and thyroid hormone alone (Yassa, Sadow and Marqusee, 2008).

10. Living with malignant struma ovarii

  • Take thyroid hormone tablets consistently, if prescribed, and have regular blood tests
  • Plan pregnancies with your team, especially after radioactive iodine
  • Discuss menopause symptoms if both ovaries were removed; hormone replacement may be possible
  • Keep follow-up appointments, as recurrence can be late
  • Look after bone health with exercise, calcium and vitamin D
  • Carry a list of your treatments, including any radioactive iodine dates
  • Seek support from ovarian and thyroid cancer charities

11. Frequently asked questions

Question Answer
How can thyroid cancer grow in the ovary? Teratomas can produce thyroid tissue, which can turn cancerous
Is it ovarian cancer or thyroid cancer? It is a thyroid-type cancer arising in the ovary
Do I need my thyroid removed? Not always; it depends on the risk features and spread
Can I still have children? Often yes, if the other ovary and womb are kept
Is the outlook good? Generally excellent
Can it come back? Yes, sometimes years later, so follow-up continues
Is it inherited? No clear inherited link is known
Will I need to be isolated after radioactive iodine? For a few days, to protect others from radiation; your team will give precise advice

12. Questions to ask your care team

  • What type of thyroid cancer was found, and what stage is it?
  • Is my case low or high risk?
  • Do I need thyroidectomy or radioactive iodine?
  • Can my fertility be preserved?
  • How will thyroglobulin be used in my follow-up?
  • Who will coordinate my care between gynaecology and endocrinology?
  • Should my neck thyroid be checked with an ultrasound?
  • What symptoms should prompt me to get in touch before my next appointment?

Resources

  1. Addley, S. et al. (2021) ‘Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10 years’, Archives of Gynecology and Obstetrics, 303(4), pp. 863-870.
  2. Cui, Y. et al. (2021) ‘The clinical and pathological characteristics of malignant struma ovarii: an analysis of 144 published patients’, Frontiers in Oncology, 11, 645156.
  3. Jenkins, C.R. et al. (2025) ‘Prognostic significance of surgically treated malignant struma ovarii with or without adjuvant thyroid-related therapy: a systematic review and meta-analysis’, World Journal of Surgery, 49(2), pp. 401-408.
  4. Yassa, L., Sadow, P. and Marqusee, E. (2008) ‘Malignant struma ovarii’, Nature Clinical Practice Endocrinology and Metabolism, 4(8), pp. 469-472.
  5. National Cancer Institute (2026) Ovarian Germ Cell Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-germ-cell-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.